North America RNA Therapeutics Market to Grow with a CAGR of 5.48% through 2029
Rising advancements in RNA technology are expected to
drive the North America RNA Therapeutics Market growth in the forecast period,
2025-2029.
According to TechSci Research report, “North America RNA
Therapeutics Market – By Country, Competition, Forecast and Opportunities, 2029F”, the North America RNA Therapeutics Market was valued at USD 12.95 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.48% through 2029.
Advancements in RNA technology have been a
pivotal driver for the growth of the North America RNA therapeutics market.
These technological breakthroughs have expanded our understanding of RNA
biology, facilitating the development of more effective and targeted therapies.
For instance, the refinement of siRNA (small interfering RNA) and ASO (antisense
oligonucleotide) technologies has allowed for precise gene silencing and
modulation, enabling the treatment of a wide range of genetic, infectious, and
chronic diseases. Innovations in RNA delivery systems have also overcome
previous challenges related to stability and cellular uptake, making it easier to
develop and administer RNA-based therapies.
The increasing prevalence of genetic disorders has
spurred the demand for RNA therapeutics. These disorders, such as cystic
fibrosis, muscular dystrophy, and Huntington's disease, are often challenging
to treat with traditional pharmaceuticals. RNA-based therapies offer a targeted
approach to correcting genetic mutations or reducing the expression of harmful
genes, potentially providing life-changing treatments for patients affected by
these conditions. The promise of personalized medicine, where therapies are
tailored to an individual's genetic makeup, further drives the market's growth.
Oncology remains a primary driver of the RNA therapeutics market. The ability
to specifically target and silence cancer-associated genes or boost the body's
immune response against cancer cells has led to the development of a new
generation of cancer therapies.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "North America RNA Therapeutics Market.”
The North America RNA Therapeutics Market is segmented
into Product, Type, Indication, End User, Country and Company.
Based on the Product, Vaccines emerged
as the dominant segment in the North America market for North America RNA
Therapeutics Market in 2023. mRNA vaccines have demonstrated
exceptional efficacy and safety profiles in preventing COVID-19, as evidenced
by their high success rates and minimal adverse effects in clinical trials and
real-world settings. This success has instilled confidence in mRNA technology
as a platform for creating highly effective vaccines. mRNA vaccines stand out
for their speed of development and deployment. The ability to design and
produce these vaccines relatively quickly has been critical in addressing
emerging infectious diseases and variants. This nimbleness in response to
evolving health threats has bolstered the demand for RNA therapeutics. he
COVID-19 pandemic posed an unprecedented North America health crisis, leading
to an urgent need for effective vaccines. mRNA vaccines emerged as a powerful
and rapid response to the pandemic. The sheer scale of the North America vaccination
campaigns has resulted in an astronomical demand for mRNA-based products,
elevating the profile of RNA therapeutics.
Based on the End User, Hospitals and
Clinics emerged as the dominant segment in the North America market for North
America RNA Therapeutics Market in 2023. Hospitals and clinics serve a broad
and diverse patient population, including those with various medical conditions
and diseases. RNA therapeutics have applications in a wide range of medical
specialties, making them relevant for the treatment of conditions such as
cancer, infectious diseases, rare genetic disorders, and cardiovascular
conditions. This diverse patient base necessitates the availability of
RNA-based therapies in these healthcare settings, contributing to the demand. Hospitals
are often the primary institutions where complex medical cases are diagnosed
and treated. RNA therapeutics, with their precision and ability to target
specific genes or pathways, are especially relevant in these complex cases.
This includes cases of advanced cancer, severe genetic diseases, and other
challenging medical conditions where standard treatment options may be limited.
RNA therapeutics can provide innovative and tailored solutions in these
scenarios
Major companies operating in North America RNA
Therapeutics Market are:
- Moderna, Inc.
- Alnylam Pharmaceuticals, Inc.
- Novartis Ag
- Ionis Pharmaceuticals, Inc.
- Sarepta Therapeutics, Inc
- Sanofi Ag
- Pfizer Inc
- Biontech SE
- Orna Therapeutics Inc.
- CPISPER Therapeutics AG
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The North
America RNA Therapeutics Market is poised for significant growth in the coming
years. Advances in RNA technology, such as mRNA vaccines' unprecedented success
against COVID-19, have spotlighted the versatility and precision of these therapies.
The emergence of personalized medicine, where treatments are
tailored to individual genetic profiles, is creating a demand for RNA
therapeutics that can provide precisely targeted solutions. Regulatory support,
research investments, and collaborations in the field continue to accelerate
the development and adoption of RNA-based therapies”, said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“North America RNA Therapeutics Market, By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Other Indications), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F”, has evaluated the future growth potential of North America RNA
Therapeutics Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in North America RNA
Therapeutics Market.
Contact Us-
TechSci Research LLC
420 Lexington Avenue, Suite
300,
New York, United States-
10170
M: +13322586602
Email: [email protected]
Website: www.techsciresearch.com